Study wrapper · #1269
Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.
Editor's note
Methodologically careful for a claims study — propensity matching, inverse-probability-of-censoring weights and pairwise censoring all address the differential-follow-up problem that usually wrecks this design. Two caveats carry weight: the cost offset applies to people who stay on therapy, which selects for tolerability and adherence, and the author list includes Eli Lilly affiliation, so the Medicare-programme framing is not disinterested. The 12- to 18-month medical-cost component was only borderline significant (p = 0.065). It is an economic argument, not a clinical outcomes finding.
Plain-language abstract
Using US claims data, researchers matched 15,843 adults over 55 with obesity or overweight who started tirzepatide against 15,843 similar people who took no incretin drug, then tracked total healthcare spending. Excluding the cost of the drug itself, the tirzepatide group's monthly costs ran about $145 lower at 6 to 12 months and about $319 lower at 12 to 18 months, driven largely by fewer inpatient and emergency visits. The authors note that a $319 monthly offset would cover the $195 monthly net Medicare cost under the Bridge programme.